CL2017001130A1 - Síntesis de copanlisib y su sal diclorhidrato - Google Patents

Síntesis de copanlisib y su sal diclorhidrato

Info

Publication number
CL2017001130A1
CL2017001130A1 CL2017001130A CL2017001130A CL2017001130A1 CL 2017001130 A1 CL2017001130 A1 CL 2017001130A1 CL 2017001130 A CL2017001130 A CL 2017001130A CL 2017001130 A CL2017001130 A CL 2017001130A CL 2017001130 A1 CL2017001130 A1 CL 2017001130A1
Authority
CL
Chile
Prior art keywords
copanlisib
synthesis
dihydrochloride salt
new
compounds
Prior art date
Application number
CL2017001130A
Other languages
English (en)
Inventor
Jan Georg Peters
Juergen Stiehl
Kai Lovis
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2017001130A1 publication Critical patent/CL2017001130A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Pyridine Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE RELACIONA CON UN NUEVO MÉTODO PARA PREPARAR COPANLISIB, Y DICLORHIDRATO DE COPANLISIB, CON NUEVOS COMPUESTOS INTERMEDIARIOS, Y CON EL USO DE DICHOS NUEVOS COMPUESTOS INTERMEDIARIOS PARA LA PREPARACIÓN DE COPANLISIB.</p>
CL2017001130A 2014-11-07 2017-05-05 Síntesis de copanlisib y su sal diclorhidrato CL2017001130A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14192202.1A EP3018131A1 (en) 2014-11-07 2014-11-07 Synthesis of copanlisib and its dihydrochloride salt

Publications (1)

Publication Number Publication Date
CL2017001130A1 true CL2017001130A1 (es) 2018-01-19

Family

ID=51866060

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001130A CL2017001130A1 (es) 2014-11-07 2017-05-05 Síntesis de copanlisib y su sal diclorhidrato

Country Status (34)

Country Link
US (1) US10035803B2 (es)
EP (2) EP3018131A1 (es)
JP (1) JP6691114B2 (es)
KR (1) KR102562286B1 (es)
CN (1) CN107074776B (es)
AR (1) AR102568A1 (es)
AU (1) AU2015341779B2 (es)
BR (1) BR112017009471B1 (es)
CA (1) CA2966796C (es)
CL (1) CL2017001130A1 (es)
CO (1) CO2017004533A2 (es)
DK (1) DK3215507T3 (es)
EA (1) EA031248B1 (es)
ES (1) ES2716730T3 (es)
HR (1) HRP20190527T8 (es)
HU (1) HUE042794T2 (es)
IL (1) IL251586B (es)
JO (1) JO3487B1 (es)
LT (1) LT3215507T (es)
MX (1) MX365111B (es)
MY (1) MY183123A (es)
NZ (1) NZ730843A (es)
PE (1) PE20170951A1 (es)
PL (1) PL3215507T3 (es)
PT (1) PT3215507T (es)
RS (1) RS58494B1 (es)
SG (1) SG11201702999XA (es)
SI (1) SI3215507T1 (es)
TR (1) TR201904346T4 (es)
TW (1) TWI697494B (es)
UA (1) UA118999C2 (es)
UY (1) UY36396A (es)
WO (1) WO2016071426A1 (es)
ZA (1) ZA201703866B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
AP2015008750A0 (en) 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
EP3018127A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EA201791974A1 (ru) 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
WO2018054782A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
TW565582B (en) * 2001-04-13 2003-12-11 Kaneka Corp Diamine, acid dianhydride, and reactive group containing polyimide composition prepared therefrom and preparing them
CN100506817C (zh) * 2001-08-15 2009-07-01 纳幕尔杜邦公司 用于防治无脊椎害虫的邻-杂环取代的芳基酰胺类化合物
WO2004029055A1 (en) * 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
CA2713388C (en) * 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
BR112012010519A2 (pt) 2009-11-04 2017-12-05 Novartis Ag derivados de sulfonamida heterocíclicos
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Also Published As

Publication number Publication date
PL3215507T3 (pl) 2019-08-30
PE20170951A1 (es) 2017-07-13
KR20170078654A (ko) 2017-07-07
SG11201702999XA (en) 2017-05-30
MX365111B (es) 2019-05-23
MX2017005891A (es) 2017-06-30
US20170327505A1 (en) 2017-11-16
ES2716730T3 (es) 2019-06-14
EA201790982A1 (ru) 2017-10-31
CN107074776B (zh) 2021-02-02
LT3215507T (lt) 2019-04-10
NZ730843A (en) 2022-12-23
TW201625633A (zh) 2016-07-16
RS58494B1 (sr) 2019-04-30
CA2966796C (en) 2022-12-06
BR112017009471B1 (pt) 2023-02-28
AU2015341779B2 (en) 2020-02-27
EP3215507B1 (en) 2018-12-26
CO2017004533A2 (es) 2017-07-19
TWI697494B (zh) 2020-07-01
IL251586B (en) 2019-05-30
MY183123A (en) 2021-02-15
SI3215507T1 (sl) 2019-04-30
DK3215507T3 (en) 2019-04-15
ZA201703866B (en) 2019-06-26
JP2017536352A (ja) 2017-12-07
UY36396A (es) 2016-06-30
HRP20190527T8 (hr) 2020-02-21
US10035803B2 (en) 2018-07-31
HUE042794T2 (hu) 2019-07-29
IL251586A0 (en) 2017-06-29
EP3215507A1 (en) 2017-09-13
CN107074776A (zh) 2017-08-18
CA2966796A1 (en) 2016-05-12
AU2015341779A1 (en) 2017-05-11
KR102562286B1 (ko) 2023-08-02
BR112017009471A2 (en) 2018-01-02
PT3215507T (pt) 2019-03-29
JO3487B1 (ar) 2020-07-05
WO2016071426A1 (en) 2016-05-12
JP6691114B2 (ja) 2020-04-28
EP3018131A1 (en) 2016-05-11
TR201904346T4 (tr) 2019-04-22
HRP20190527T1 (hr) 2019-05-17
UA118999C2 (uk) 2019-04-10
AR102568A1 (es) 2017-03-08
EA031248B1 (ru) 2018-12-28

Similar Documents

Publication Publication Date Title
AR132627A2 (es) Procesos para preparar compuestos intermediarios de utilidad para sintetizar compuestos de carbamoilpiridona policíclicos
CL2017001131A1 (es) Síntesis de copanlisib y su sal diclorhidrato
CR20160098A (es) Polimorfo de los inhibidores de la syk
EA201692219A1 (ru) Способы получения противовирусных соединений
BR112016022691A2 (pt) uso de compostos heterocíclicos para controlar nematódeos.
UY36396A (es) Síntesis de copanlisib y su sal diclorhidrato
TW201613866A (en) Process for preparing fluorinated iminopyridine compounds
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
HUE053376T2 (hu) Poliuretánok elõállításában történõ alkalmazásra megfelelõ, nitrogént tartalmazó vegyületek
BR112016026046A2 (pt) Uso de compostos de tienotriazolodiazepina
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
CL2017002255A1 (es) Procesos para preparar fluorocetólidos.
MX389099B (es) Proceso para la preparación de 3-cloro-2-vinilfenilsulfonatos.
MX2016015624A (es) Proceso para la preparacion de derivados de tiazol.
MX2016015623A (es) Proceso para la preparacion de derivados dihidroisoxazol.
MX2016016398A (es) Preparacion de piperidin-4-carbotioamida.
UY36284A (es) Método para la preparación de imidazopiridazinas sustituidas
UA31482S (uk) Сторінка документа для виїзду за кордон
UA31481S (uk) Сторінка документа для виїзду за кордон